A phase‐1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study

We performed a phase‐1 pharmacokinetic optimal dosing study of intraventricular topotecan (IT), administered daily 5×, to determine whether, the maximum tolerated dose of IT topotecan was also the pharmacokinetic optimal dose.

[1]  P. Adamson,et al.  Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: A Children's Oncology Group trial (P9962) , 2012, Pediatric blood & cancer.

[2]  J. Farrar,et al.  Dexamethasone, Cerebrospinal Fluid Matrix Metalloproteinase Concentrations and Clinical Outcomes in Tuberculous Meningitis , 2009, PloS one.

[3]  Ruopeng Sun,et al.  Dexamethasone regulation of matrix metalloproteinase expression in experimental pneumococcal meningitis , 2008, Brain Research.

[4]  M. Gilbert,et al.  A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. , 2008, Neuro-oncology.

[5]  D. Alsop,et al.  Cerebrospinal Fluid Research Cerebrospinal Fluid Matrix Metalloproteinase-9 Increases during Treatment of Recurrent Malignant Gliomas , 2022 .

[6]  J. Panetta,et al.  Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. , 2006, Neuro-oncology.

[7]  S. Kiechl,et al.  Vascular endothelial growth factor in CSF , 2000, Neurology.

[8]  P. Adamson,et al.  Intraventricular concentration times time (C × T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma , 1999, Cancer.

[9]  P. Houghton,et al.  Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Klempner,et al.  Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis , 1998, Cancer.

[11]  F. Balkwill,et al.  Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. , 1997, Analytical biochemistry.

[12]  George Casella,et al.  Refining binomial confidence intervals , 1986 .

[13]  C. Blyth,et al.  Binomial Confidence Intervals , 1983 .

[14]  A. Silvani,et al.  Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers , 2009, Clinical chemistry and laboratory medicine.

[15]  Angela Tam,et al.  Matrix metalloprotease-9 in cerebrospinal fluid correlates with disease activity in lymphomatous meningitis. , 2007, Clinical Lymphoma & Myeloma.

[16]  P. Houghton,et al.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors , 2004, Cancer Chemotherapy and Pharmacology.

[17]  F. Balis,et al.  Intrathecal administration of topotecan in nonhuman primates , 2004, Cancer Chemotherapy and Pharmacology.

[18]  K. Matthay,et al.  Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.